Buscar
Mostrando ítems 1-10 de 810
Granular cell tumour (Abrikossoff's tumour): Case series
(2006-05-01)
This case series describes three unreported cases of an uncommon benign neoplasm named Abrikossoff's tumour or granular cell tumour (GCT). This mesenchymal neoplasm apparently arises from neural or Schwann cell origin with ...
Granular cell tumour (Abrikossoff's tumour): Case series
(2006-05-01)
This case series describes three unreported cases of an uncommon benign neoplasm named Abrikossoff's tumour or granular cell tumour (GCT). This mesenchymal neoplasm apparently arises from neural or Schwann cell origin with ...
Immunohistochemical evaluation of prostaglandin E2 and vascular endothelial growth factor in canine cutaneous mast cell tumours
(Wiley-Blackwell Publishing, Inc, 2010-03-01)
Vascular endothelial growth factor (VEGF) and prostaglandin E2 (PGE-2) appear to play a critical role in tumour neovascularization. In this study, we have investigated the expression of VEGF and PGE-2 in 53 canine cutaneous ...
Existence of solutions and optimal control for a model of tissue invasion by solid tumours
(Journal of Mathematical Analysis and Applications, 2018)
Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy
(2010-05-13)
Abstract
Background
Phagocytosis of apoptotic cells by macrophages induces a suppressor phenotype. Previous data from our group suggested that this occurs via Platelet-activating ...
Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy
(2010-05-13)
Abstract
Background
Phagocytosis of apoptotic cells by macrophages induces a suppressor phenotype. Previous data from our group suggested that this occurs via Platelet-activating ...
Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma
(2019-01-01)
Our lack of understanding of the immune microenvironment in canine osteosarcoma (cOSA) has limited the identification of potential immunotherapeutic targets. In particular, our ability to utilize readily available tissue ...
Neuron-specific enolase is produced by neuroendocrine tumours
(The Lancet, 2016)